PV
Palvella Therapeutics, Inc.
PVLA · NASDAQ
$150.56 -2.10% (-$3.23)
1M +3.30%
Market Cap $2.16B
P/E Ratio -
Div. Yield -
ROE 47.84%
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/B 9.96x
EV/EBITDA N/A
P/S N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 47.84%
ROA 24.34%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 21.18x
Int. coverage -7.92x
Debt/Equity 0.00x
Stability
19 /100
Unstable EPS volatility 154.66%
Profitable years 0
Beta -0.17x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na PVLA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Wesley H. Kaupinen
Employees
29
Headquarters
Wayne
Nadcházející události
10 LIS
Earnings
Upcoming earnings report